We are live on ! Find out more
SRTA

Strata Critical Medical Inc

120 hedge funds and large institutions have $121M invested in Strata Critical Medical Inc in 2024 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 43 increasing their positions, 30 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

273% more call options, than puts

Call options by funds: $317K | Put options by funds: $85K

43% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 30

20% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 15

2.67% more ownership

Funds ownership: 50.18%52.85% (+2.7%)

3% more funds holding

Funds holding: 117120 (+3)

10% less capital invested

Capital invested by funds: $135M → $121M (-$13.7M)

Holders
120
Holders Change
+3
Holders Change %
+2.56%
% of All Funds
1.72%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
18
Increased
43
Reduced
30
Closed
15
Calls
$317K
Puts
$85K
Net Calls
+$232K
Net Calls Change
+$106K
Name Holding Trade Value Shares
Change
Change in
Stake
BIP
26
Bouvel Investment Partners
Pennsylvania
$790K -$6.55K -2,058 -0.8%
DRS
27
Deane Retirement Strategies
Louisiana
$737K +$1.72K +541 +0.2%
Russell Investments Group
28
Russell Investments Group
United Kingdom
$671K +$710K +223,197 +4,372%
QOP
29
Quinn Opportunity Partners
Virginia
$669K
BFM
30
Boothbay Fund Management
New York
$617K +$503K +157,889 +303%
Boston Partners
31
Boston Partners
Massachusetts
$614K +$665K +208,955 New
IP
32
Intellectus Partners
California
$558K -$25K -7,850 -4%
Citadel Advisors
33
Citadel Advisors
Florida
$503K +$464K +145,866 +576%
Charles Schwab
34
Charles Schwab
California
$500K +$32.7K +10,272 +6%
Barclays
35
Barclays
United Kingdom
$488K +$178K +56,079 +51%
UBS Group
36
UBS Group
Switzerland
$453K +$174K +54,758 +55%
Bank of New York Mellon
37
Bank of New York Mellon
New York
$395K -$170K -53,497 -28%
RhumbLine Advisers
38
RhumbLine Advisers
Massachusetts
$393K +$150K +47,210 +55%
DC
39
Diametric Capital
Massachusetts
$373K -$49.5K -15,556 -11%
AGC
40
Aspen Grove Capital
Colorado
$368K
Invesco
41
Invesco
Georgia
$325K -$1.8K -565 -0.5%
SPA
42
Sherbrooke Park Advisers
New York
$325K +$123K +38,755 +54%
American Century Companies
43
American Century Companies
Missouri
$292K +$50.8K +15,972 +19%
Marshall Wace
44
Marshall Wace
United Kingdom
$282K +$305K +95,849 New
GC
45
Guggenheim Capital
Illinois
$262K -$11.2K -3,503 -4%
Millennium Management
46
Millennium Management
New York
$237K -$44.7K -14,035 -15%
XT
47
XTX Topco
Cayman Islands
$217K +$186K +58,545 +385%
MS
48
Maven Securities
Jersey
$206K +$223K +70,000 New
AllianceBernstein
49
AllianceBernstein
Tennessee
$177K +$23.8K +7,490 +14%
PCM
50
Prelude Capital Management
New York
$141K -$13.7K -4,307 -8%

SRTA Hedge Fund Activity: Q3 2024 in Review

120 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Strata Critical Medical Inc (SRTA) for Q3 2024, worth a combined $121M — down 10% from $135M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new SRTA positions and 15 closed out — a net gain of 3 holders — while 43 added to existing stakes and 30 trimmed.

The largest buyer was ARK Investment Management, adding an estimated $2.46M. The largest seller was Northern Right Capital Management, exiting entirely with an estimated $4.02M sold.

  • 120 institutional investors held Strata Critical Medical Inc (SRTA) as of Q3 2024, up from 117 in Q2 2024.
  • Funds reported $121M of Strata Critical Medical Inc stock for Q3 2024, down 10% quarter-over-quarter.
  • 18 funds opened new Strata Critical Medical Inc positions in Q3 2024 and 15 closed out, a net change of +3 holders.
  • The largest Strata Critical Medical Inc buyer in Q3 2024 was ARK Investment Management, an estimated $2.46M added.
  • The largest Strata Critical Medical Inc seller in Q3 2024 was Northern Right Capital Management, an estimated $4.02M sold.

Based on aggregated 13F filings for Q3 2024.